Enfortumab Vedotin

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.

**Synonyms:** - AGS 22ME - AGS-22M6E - ASG 22CE - ASG-22CE - ASG22CE - Anti-Nectin 4 ADC ASG-22CE - Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E - ENFORTUMAB VEDOTIN - Enfortumab Vedotin-ejfv - Enfortumab vedotin - Padcev